PubRank

A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both

Clinical Trial ID NCT00480558

PubWeight™ 4.87‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00480558

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994 14.96
2 Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004 6.46
3 Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996 5.38
4 Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003 4.08
5 Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001 2.31
6 Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 2011 1.29
7 Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006 1.25
8 A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012 1.09
9 The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS One 2014 0.95
10 Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines. Hum Vaccin Immunother 2012 0.79
11 Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. BMC Infect Dis 2014 0.75
Next 100